These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 18368510)

  • 1. Bone and mineral disorders in pre-dialysis CKD.
    Kovesdy CP; Kalantar-Zadeh K
    Int Urol Nephrol; 2008; 40(2):427-40. PubMed ID: 18368510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
    Martin KJ; González EA
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Control of phosphorus and treatment with vitamin D in chronic kidney disease prior to the start of dialysis].
    Sánchez González MC; Fernandez Giraldez E; Valdivielso Revilla JM
    Nefrologia; 2008; 28 Suppl 5():39-45. PubMed ID: 18847419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Management of bone and mineral metabolism disorders before the dialysis stage remains still perfectible. Data from the French Phosphorus and Calcium Survey Photo-Graphe].
    Jean G; Daugas É; Roth H; Drueke T; Bouchet JL; Hannedouche T; London G; Fouque D
    Nephrol Ther; 2017 Nov; 13(6):470-478. PubMed ID: 28843391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of kidney function, vitamin D deficiency, and circulating markers of mineral and bone disorders in CKD.
    Ureña-Torres P; Metzger M; Haymann JP; Karras A; Boffa JJ; Flamant M; Vrtovsnik F; Gauci C; Froissart M; Houillier P; Stengel B;
    Am J Kidney Dis; 2011 Oct; 58(4):544-53. PubMed ID: 21803465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The challenge of controlling phosphorus in chronic kidney disease.
    Cannata-Andía JB; Martin KJ
    Nephrol Dial Transplant; 2016 Apr; 31(4):541-7. PubMed ID: 25770169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Disturbance of phosphorus metabolism in chronic kidney disease].
    Komaba H; Fukagawa M
    Clin Calcium; 2009 Feb; 19(2):166-72. PubMed ID: 19182354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Vitamin D Metabolites with Parathyroid Hormone, Fibroblast Growth Factor-23, Calcium, and Phosphorus in Dogs with Various Stages of Chronic Kidney Disease.
    Parker VJ; Harjes LM; Dembek K; Young GS; Chew DJ; Toribio RE
    J Vet Intern Med; 2017 May; 31(3):791-798. PubMed ID: 28186657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disordered mineral metabolism and vascular calcification in nondialyzed chronic kidney disease patients.
    Mehrotra R
    J Ren Nutr; 2006 Apr; 16(2):100-18. PubMed ID: 16567266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of vitamin D in the pathogenesis of chronic kidney disease].
    Cozzolino M; Brunini F; Capone V; Ricca F; Kwaidri Y; Montanari E; Cusi D
    Recenti Prog Med; 2013 Jan; 104(1):33-40. PubMed ID: 23439539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved patient outcomes in chronic kidney disease: optimizing vitamin D therapy.
    Gesek FA; Desmond JS
    Nephrol Nurs J; 2008; 35(2 Suppl):5S-22S; quiz 23S. PubMed ID: 18505229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of FGF23-Klotho axis in CKD-MBD].
    Komaba H
    Clin Calcium; 2010 Jul; 20(7):1028-36. PubMed ID: 20585181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast Growth Factor-23 Concentration in Dogs with Chronic Kidney Disease.
    Harjes LM; Parker VJ; Dembek K; Young GS; Giovaninni LH; Kogika MM; Chew DJ; Toribio RE
    J Vet Intern Med; 2017 May; 31(3):784-790. PubMed ID: 28419560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D compounds for people with chronic kidney disease requiring dialysis.
    Palmer SC; McGregor DO; Craig JC; Elder G; Macaskill P; Strippoli GF
    Cochrane Database Syst Rev; 2009 Oct; (4):CD005633. PubMed ID: 19821349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone mineral metabolism and its relationship to kidney disease in a residential care home population: a cross-sectional study.
    Carter JL; O'Riordan SE; Eaglestone GL; Delaney MP; Lamb EJ
    Nephrol Dial Transplant; 2008 Nov; 23(11):3554-65. PubMed ID: 18544628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.
    Gutierrez O; Isakova T; Rhee E; Shah A; Holmes J; Collerone G; Jüppner H; Wolf M
    J Am Soc Nephrol; 2005 Jul; 16(7):2205-15. PubMed ID: 15917335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperphosphatemia and hyperparathyroidism in incident chronic kidney disease patients.
    Ramos AM; Albalate M; Vázquez S; Caramelo C; Egido J; Ortiz A
    Kidney Int Suppl; 2008 Dec; (111):S88-93. PubMed ID: 19034335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
    Koizumi M; Komaba H; Fukagawa M
    Contrib Nephrol; 2013; 180():110-23. PubMed ID: 23652554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.